 PHILADELPHIA, Jan. 05, 2023 GLOBE NEWSWIRE -- Cabaletta Bio, Inc. Nasdaq: CABA, a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Thursday, January 12th at 7:30 a.m. PT 10:30 a.m. ET. 